La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
BARCELONA, Spain I July 1, 2021 I La Merie Publishing announced the release of its newest report about in vivo delivery of nucleic acid-encoded antibodies . The report “Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an...
BARCELONA, Spain I May 14, 2020 I La Merie Publishing announced the release of its newest report about Targeted Protein Degradation. The report “Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective” provides a landscape...
June 11, 2019 I We just released a new report describing and analyzing the field of bispecific antibodies used to redirect T-cells or natural killer (NK) cells to tumor cells. Since our first report about this subject three years ago, this specific field of biopharmaceutical research has grown enormously as...
April 4, 2018 I We just concluded our annual compilation and analysis of sales of recombinant therapeutic antibodies and proteins for the year 2018. The results show another all time high of global sales of more than US$ 202 mln, a plus of 7.3% compared with the previous year. The...
January 16, 2019 I We just released a management report for free download (see our menu „FREE reports“) in which we analyzed key financial data from the TOP 25 pharma-based health care companies with revenues of more than US$ 10 bln in the fiscal year 2017. The report entitled „TOP...
STUTTGART, Germany I June 19, 2018 I La Merie Publishing released the results of an independent search for and evaluation of PD-1 and PD-L1 immune checkpoint inhibitors in preclinical and clinical development by pharmaceutical companies. This Competitive Intelligence report analyzes the competitive field of PD-1 and PD-L1 Immune Checkpoint Inhibitors...
STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...
STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies fortreatment of cancer and inflammatory diseases, especially the emerging immuno-oncology antibodies and...
